This week, we dissect the EU's surprising new cybersecurity guidance for AI medical devices. Released just last week, this new framework moves beyond traditional compliance, demanding that MedTech innovators build dynamic, continuous defenses against sophisticated AI-specific threats like adversarial attacks and model drift.

This shift creates immediate, complex challenges for companies that previously achieved CE marking. We explore how this new regulatory layer requires a complete rethinking of post-market surveillance and the integration of data science and cybersecurity into the core regulatory affairs function.

**Case Study Spotlight:** A promising German AI diagnostic company celebrated its EU market entry last year. Now, their market access is at risk. Are they prepared to continuously prove their AI model's integrity and defend against data pipeline breaches under the new rules?

**Key Takeaways:**

* Is your current Quality Management System equipped to handle dynamic AI model monitoring and re-validation?

* How can you differentiate between natural algorithm drift and a malicious adversarial attack?

* What new technical expertise does your regulatory team need to acquire immediately?

* Does your post-market surveillance plan meet the new demands for continuous model integrity reporting?

* How will you manage the secure data pipeline required from the hospital network to your servers?

* Are your current cybersecurity protocols robust enough to prevent data poisoning?

* What is the most efficient way to update your technical documentation to reflect these new dynamic processes?

To navigate the evolving global regulatory landscape, contact us at [email protected] or visit https://pureglobal.com/. For a suite of free AI-powered regulatory tools and access to a medical device database, visit https://pureglobal.ai/.